Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 3075-3078

  Dong, Linda M ^a   Shu, Xiao Ou ^b   Gao, Yu Tang ^c   Milne, Ginger ^b   Ji, Bu Tian ^a   Yang, Gong ^b   Li, Hong Lan ^c   Rothman, Nathaniel ^a   Zheng, Wei ^b   Chow, Wong Ho ^a   Abnet, Christian C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANGHAI CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

11ALPHA HYDROXY 9,15 DIOXO 2,3,4,5 TETRANORPROSTANE 1,20 DIOIC ACID; BACTERIUM ANTIBODY; CREATININE; IMMUNOGLOBULIN G; MULTIVITAMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; 7 HYDROXY 5,11 DIOXOTETRANORPROSTANE 1,16 DIOIC ACID; 7-HYDROXY-5,11-DIOXOTETRANORPROSTANE-1,16-DIOIC ACID; PROSTAGLANDIN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG USE; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MEAL; MENOPAUSE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTAGLANDIN URINE LEVEL; STOMACH CANCER; URINALYSIS; WOMEN'S HEALTH; CANCER STAGING; CASE CONTROL STUDY; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GENETICS; HELICOBACTER INFECTION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STOMACH TUMOR; URINE;

ADULT; AGED; CASE-CONTROL STUDIES; CHINA; COHORT STUDIES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTAGLANDINS; RISK FACTORS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 72749110291     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0680     Document Type: Article

References (26)

1. Grau MV, Rees JR, Baron JA. Chemoprevention in gastrointestinal cancers: current status. Basic Clin Pharmacol Toxicol 2006;98:281-287
2. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511-523 (Pubitemid 30216052)
3. Fortuny J, Johnson CC, Bohlke K, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 2007;5:1154-9e3. (Pubitemid 47488964)
4. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:444-450 (Pubitemid 40270110)
5. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001;84:965-968 (Pubitemid 32385841)
6. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
7. Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population- based study. Cancer Epidemiol Biomarkers Prev 2004;13:34-39 (Pubitemid 38116618)
8. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003;3:28. (Pubitemid 38851321)
9. Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-1791
10. Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal antiinflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009;100:551-557
11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235
12. Whittle BJ, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271-273
13. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 2004:301-310
14. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-525 (Pubitemid 30111473)
15. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-1280 (Pubitemid 27152551)
16. Konturek SJ, Konturek PC, Hartwich A, Hahn EG. Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. Regul Pept 2000;93:13-19 (Pubitemid 30734345)
17. 2 in human colon cancer cells. Cancer Res 1998;58:362-366
18. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-18081 (Pubitemid 37411372)
19. 2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-275
20. Frolich JC, Wilson TW, Sweetman BJ, et al. Urinary prostaglandins. Identification and origin. J Clin Invest 1975;55:763-770
21. Zheng W, Chow WH, Yang G, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol 2005;162:1123-1131 (Pubitemid 41746625)
22. 2 metabolite and colorectal cancer risk. J Clin Oncol 2006;24:5010-5016
23. Lewis GP, Piper PJ. Inhibition of release of prostaglandins as an explanation of some of the actions of anti-inflammatory corticosteroids. Nature 1975;254:308-311
24. van Rees BP, Sivula A, Thoren S, et al. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 2003;107:551-556 (Pubitemid 37296114)
25. Liu Z, Wang X, Lu Y, et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008;29:1219-1227 (Pubitemid 351958702)
26. 2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2006;4:1358-1365